Systemic interferon type I and type II signatures in primary Sjögren's syndrome reveal differences in biological disease activity

Rheumatology
Iris L A BodewesMarjan A Versnel

Abstract

To assess the relationships between systemic IFN type I (IFN-I) and II (IFN-II) activity and disease manifestations in primary SS (pSS). RT-PCR of multiple IFN-induced genes followed by principal component analysis of whole blood RNA of 50 pSS patients was used to identify indicator genes of systemic IFN-I and IFN-II activities. Systemic IFN activation levels were analysed in two independent European cohorts (n = 86 and 55, respectively) and their relationships with clinical features were analysed. Three groups could be stratified according to systemic IFN activity: IFN inactive (19-47%), IFN-I (53-81%) and IFN-I + II (35-55%). No patient had isolated IFN-II activation. IgG levels were highest in patients with IFN-I + II, followed by IFN-I and IFN inactive patients. The prevalence of anti-SSA and anti-SSB was higher among those with IFN activation. There was no difference in total-EULAR SS Disease Activity Index (ESSDAI) or ClinESSDAI between the three subject groups. For individual ESSDAI domains, only the biological domain scores differed between the three groups (higher among the IFN active groups). For patient reported outcomes, there were no differences in EULAR Sjögren's syndrome patient reported index (ESSPRI), fatigue o...Continue Reading

References

Nov 1, 1984·Seminars in Arthritis and Rheumatism·R I FoxP Michelson
Jun 1, 1983·Acta Psychiatrica Scandinavica·A S Zigmond, R P Snaith
Apr 1, 1995·Journal of Psychosomatic Research·E M SmetsJ C De Haes
May 3, 2001·Quality of Life Research : an International Journal of Quality of Life Aspects of Treatment, Care and Rehabilitation·M J SchroeversA V Ranchor
Feb 16, 2002·Methods : a Companion to Methods in Enzymology·K J Livak, T D Schmittgen
May 15, 2002·Annals of the Rheumatic Diseases·C VitaliUNKNOWN European Study Group on Classification Criteria for Sjögren's Syndrome
Dec 14, 2004·Arthritis and Rheumatism·Kyriakos A KirouMary K Crow
Feb 16, 2006·Proceedings of the National Academy of Sciences of the United States of America·Jacques-Eric GottenbergXavier Mariette
May 19, 2007·The British Journal of Ophthalmology·Akio OishiNagahisa Yoshimura
Jun 27, 2008·European Journal of Immunology·Manon E WildenbergMarjan A Versnel
Nov 28, 2008·Arthritis and Rheumatism·Barbara SegalKathy Moser
May 1, 2009·Genes and Immunity·E S EmamianK L Moser
Jun 13, 2009·Arthritis Research & Therapy·Sherine E Gabriel, Kaleb Michaud
Jun 30, 2009·Annals of the Rheumatic Diseases·Raphaèle SerorUNKNOWN EULAR Sjögren's Task Force
Oct 15, 2011·Arthritis Research & Therapy·Karstein HaldorsenJohan Gorgas Brun
Sep 13, 2012·The Journal of Clinical Psychiatry·Marc UdinaRocío Martín-Santos
Oct 10, 2012·Proceedings of the National Academy of Sciences of the United States of America·John C HallAntony Rosen
Jul 9, 2013·Annals of the Rheumatic Diseases·Naomi I MariaMarjan A Versnel
May 20, 2015·Arthritis & Rheumatology·John C HallLivia Casciola-Rosen
Aug 15, 2015·Clinical Rheumatology·Cécile L OvermanRinie Geenen
Sep 1, 2015·Arthritis Care & Research·Theofanis KarageorgasClio P Mavragani
May 7, 2016·Annals of the Rheumatic Diseases·Raphaèle SerorUNKNOWN EULAR Sjögren Task Force
Jan 29, 2017·Arthritis & Rheumatology·Richard FurieUNKNOWN CD1013 Study Investigators

❮ Previous
Next ❯

Citations

Sep 4, 2018·Expert Review of Clinical Immunology·Iris L A Bodewes, Marjan A Versnel
Nov 15, 2018·International Journal of Molecular Sciences·Yoko OgawaKazuo Tsubota
Feb 17, 2019·Rheumatology·Juliana Imgenberg-KreuzGunnel Nordmark
Feb 17, 2019·Rheumatology·Iris L A BodewesMarie Wahren-Herlenius
Mar 1, 2019·Rheumatology·Roald OmdalKatrine Brække Norheim
Feb 29, 2020·Journal of Internal Medicine·A BjörkM Wahren-Herlenius
Jun 18, 2019·Lupus Science & Medicine·Mary K Crow, Lars Ronnblom
Jun 7, 2020·Vaccines·Chiara RizzoGiuliana Guggino
Apr 30, 2019·Rheumatology·Robert I FoxThomas Dörner
Mar 14, 2019·Frontiers in Immunology·Iris L A BodewesMarjan A Versnel
Dec 16, 2019·Clinical Rheumatology·Jorge López-MoralesGabriela Hernández-Molina
May 30, 2019·Frontiers in Immunology·Tomas MustelinNatalia V Giltiay
Aug 21, 2019·Frontiers in Immunology·Juliana Imgenberg-KreuzGunnel Nordmark
Jul 8, 2020·International Journal of Molecular Sciences·Joanna PapinskaUmesh S Deshmukh
Nov 2, 2018·International Journal of Molecular Sciences·Muhammad Shahnawaz SoyfooChristine Delporte
Dec 17, 2020·Clinical Immunology : the Official Journal of the Clinical Immunology Society·Clio P MavraganiMary K Crow
Jan 22, 2021·Autoimmunity Reviews·Muhammad S Soyfoo, Charles Nicaise
Feb 6, 2021·Journal of Clinical Medicine·Erika Huijser, Marjan A Versnel
Apr 4, 2021·International Journal of Molecular Sciences·Toshimasa ShimizuAtsushi Kawakami
May 1, 2021·International Journal of Molecular Sciences·Merri-Grace AllredScott M Lieberman
Jun 12, 2021·Nature Communications·Perrine SoretJacques-Olivier Pers
Aug 3, 2021·Frontiers in Immunology·Juliana Imgenberg-KreuzGunnel Nordmark

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cardiomyopathy

Cardiomyopathy is a disease of the heart muscle, that can lead to muscular or electrical dysfunction of the heart. It is often an irreversible disease that is associated with a poor prognosis. There are different causes and classifications of cardiomyopathies. Here are the latest discoveries pertaining to this disease.